-
Study aim
-
Determining a better approach for treatment of patients with dyspepsia
-
Design
-
The double blind randomized placebo-controlled clinical trial with independent groups, phase III, on 100 patients (50 in each group). For randomization, computer program will be used.
-
Settings and conduct
-
All patients will be visited by the physician, who recruits the patients into the study according to the inclusion and exclusion criteria. Based on the computer codes. The patients will be categorized into two groups and will receive the drugs in sealed packets without name.
-
Participants/Inclusion and exclusion criteria
-
Patients older than 18 years old, who referred with chronic dyspepsia to GI clinic of Loghman Hakim hospital, candidate of upper endoscopy without history of Helicobacter treatment, using antibiotics in the past four weeks, severe heart failure, renal failure, pulmonary failure, and renal failure were included
-
Intervention groups
-
Group A patients with dyspepsia receiving 4 drugs of furazolidone, amoxicillin, bismuth, and pantoprazole with probiotic
Group B patients with dyspepsia receiving 4 drugs of furazolidone, amoxicillin, bismuth, and pantoprazole without probiotic
-
Main outcome variables
-
Response to treatment, adherence to treatment, and complications of drug regimens in the two groups